F
Frank H. Ebetino
Researcher at Warner Chilcott
Publications - 119
Citations - 3354
Frank H. Ebetino is an academic researcher from Warner Chilcott. The author has contributed to research in topics: Bisphosphonate & Bone resorption. The author has an hindex of 29, co-authored 119 publications receiving 3160 citations. Previous affiliations of Frank H. Ebetino include Procter & Gamble & Structural Genomics Consortium.
Papers
More filters
Journal ArticleDOI
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Roslin Russell,Zhidao Xia,James E. Dunford,Udo Oppermann,Aaron Kwaasi,Philippa A. Hulley,Kathryn L. Kavanagh,James T. Triffitt,Mark W. Lundy,Roger J. Phipps,Bobby Lee Barnett,F P Coxon,Michael J. Rogers,Nelson B. Watts,Frank H. Ebetino +14 more
TL;DR: Each BP has a unique profile that may help to explain potential important clinical differences among the BPs, in terms of speed of onset of fracture reduction, antifracture efficacy at different skeletal sites, and the degree and duration of suppression of bone turnover.
Journal ArticleDOI
Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages
Steven P. Luckman,Steven P. Luckman,F P Coxon,F P Coxon,Frank H. Ebetino,R. Graham G. Russell,Michael J. Rogers +6 more
TL;DR: There is strong evidence that BPs with a heterocyclic, nitrogen‐containing side chain, such as risedronate, inhibit osteoclast‐mediated bone resorption and induce J774 apoptosis by preventing protein prenylation.
Journal ArticleDOI
Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
TL;DR: It is becoming increasingly clear that bisphosphonates may also target the osteocyte network and prevent osteocyte apoptosis, which could contribute to their anti-fracture effects and Bone mineral affinity is likely to influence the extent of any such effects of these agents on non-osteoclast cells.
Patent
Melanocortin receptor ligands
TL;DR: In this paper, the MC-4 and/or MC-3 receptor ligands having a structure according to Formula (I) have been described, wherein B, X, Z, D, G, R, R?1, R1', R11?, m, n, p, and q are as described in the specification.
Journal ArticleDOI
Structure–Activity Relationships Among the Nitrogen Containing Bisphosphonates in Clinical Use and Other Analogues: Time-Dependent Inhibition of Human Farnesyl Pyrophosphate Synthase
James E. Dunford,Aaron Kwaasi,Michael J. Rogers,Bobby Lee Barnett,Frank H. Ebetino,R Graham G Russell,Udo Oppermann,Kathryn L. Kavanagh +7 more
TL;DR: This work investigated features of N-BPs that confer maximal slow and tight-binding by quantifying the initial and final K(i)s and calculating the isomerization constant K(isom) for many N- BPs and reveals that the isomership constant and the final inhibition of FPPS by N-bPs are closely linked to antiresorptive efficacy.